OUR NEWS

FDA opens official investigation into Daily Harvest crumbles after reports of illness

July 01, 2022

The FDA has announced it is investigating an outbreak of ‘adverse reactions’ to Daily Harvest’s Crumbles, specifically the French Lentil & Leek flavour. Daily harvest recalled the item in line with complaints from consumers.

At least 133 reports of ‘adverse events’ have been received by the Food and Drug Administration (FDA) from consumers. The product was shipped nationwide throughout the United States.

“In response to Consumer Adverse Event Reports (CAERS) and Consumer Complaints submitted to the FDA, the FDA has initiated an investigation, including an inspection and sample collection in an effort to determine the cause of illnesses,” a spokesperson said.

“If you experience symptoms including yellowing of the skin and eyes (jaundice), dark urine, itching with no rash, gastrointestinal illness, nausea, fatigue, body aches, severe abdominal pain and/or fever after consuming this product, please consult with your healthcare provider.”

Daily Harvest Crumble Recall

On 17 June, Daily Harvest recalled the crumble product after it received complaints from consumers of gastrointestinal illnesses and abnormal liver function. Some patients also reported having to have their gallbladders removed.

In total, more than 470 reports of illnesses have been reported on social media, the FDA’s reporting system, and to legal professionals like PGMBM. Of those reported, 42 people required hospitalization.

Harris Pogust, Founding Partner and Chairman at PGMBM, said: “We have been hearing reports of sickness directly and through social media for a number of days now. We would urge anyone who has become ill after consuming the product to get in touch with us so that we can continue our investigations and help you as best we can.

“If you still have this product in your home, please follow FDA advice and do not consume it.”

More than 28,000 packages of the product were distributed to consumers from 28 April to 17 June through online sales, direct delivery, and at Daily Harvest stores.

Daily Harvest issued a credit for the recalled product and they, and the FDA, are recommending that consumers dispose of the product.

Sickness arising from crumble

Most people who have reported sickness have been women between the ages of 25 and 45. They have many symptoms consistent with a type of liver disease such as hepatitis, but at least 20 of them have had to have their gallbladders removed.

Daily Harvest’s Crumble was recalled nationwide, but the states where people have reported sickness from the Daily Harvest crumble are California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa, Indiana, Massachusetts, Maryland, Michigan, Missouri, Montana, New Hampshire, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Virginia, Washington, and Wisconsin.

FDA’s investigation is ongoing, and more information will be provided as it becomes available.

Please get in touch with us and let your healthcare provider know you have recently consumed the recalled Daily Harvest French Lentil & Leek Crumbles.

Contact us

We are looking into the Daily Harvest Recall, so please get in touch if you think you might have a claim.

TOLL-FREE: 888-348-6787
PHONE: 610-941-4204
EMAIL: Joshua Neuman, Associate or Jordyn Mitzman, Associate.

SHARE NOW

Latest news

30 September 2022

Forced Arbitration and Consumer Contracts

22 September 2022

Victims of Brazil’s ‘sinking city’ receive positive news to have case heard in the Netherlands

22 September 2022

Pogust Goodhead's Alicia Alinia appears on Reasons to be Cheerful podcast with Ed Miliband and Geoff Lloyd

21 September 2022

Two Million Baby Swings and Rockers Recalled Due to Strangulation Hazard

21 September 2022

The Difference Between Class Action and Mass Tort in US Law

21 September 2022

Pennsylvania Marches Towards Enacting State Drinking Water Standards for Toxic PFOA and PFOS

14 September 2022

Camp Lejeune Toxic Water Contamination

14 September 2022

EXPERTISE FILTER - CAMP LEJEUNE TOXIC WATER CONTAMINATION

30 August 2022

EPA Takes Major Steps to Protect the Public from Toxic PFOS and PFOA in U.S. Drinking Water

18 August 2022

A comment for the legal community on the BHP appeal decision

CONNECT WITH US

TRUST CENTRE

PRIVACY POLICY

complaints policy

Pogust Goodhead (a trading name of PGMBM Law Ltd)

SRA License Number 512898.

Pogust Goodhead is authorised and regulated by the Solicitors Regulation Authority and complies with the Solicitors Code of Conduct, a copy of which can be located here.

Pogust Goodhead (a trading name of PGMBM Law Ltd) SRA License Number 512898.

Pogust Goodhead is authorised and regulated by the Solicitors Regulation Authority and complies with the Solicitors Code of Conduct, a copy of which can be located here.

CONNECT WITH US

TRUST CENTRE

COMPLAINTS POLICY

NOAH WORTMAN

Director – Global Collective Redress

As Director – Global Collective Redress at PGMBM, Noah brings his extensive experience in assessing and analyzing corporate misconduct in the financial markets, as well as his commitment to finding global litigation and shareholder engagement solutions to investors across the world. He has extensive experience advocating for global investors, promoting corporate governance and investor stewardship, and implementing strategies to achieve collective redress.

Noah splits his time between Philadelphia and London with a global remit where he strives to provide access to justice for global institutional investors (including financial institutions, superannuation schemes, asset managers and owners, and sovereign wealth and pension funds) and others via engagement and litigation strategies including global shareholder litigation (class/group, opt-out/direct, and opt-in), antitrust/competition/cartel litigation, complex financial litigation, global privacy/data breach litigation, and global patent litigation.

Most recently, Noah was Senior Manager, Collective Redress at Omni Bridgeway where he worked with global institutional investors to implement litigation funding strategies to aid in exercising their shareholder rights in seeking legal redress from publicly listed companies where an alleged wrongdoing had occurred.

Previously, Noah was Managing Director, Americas and Global Head of Class Action Services for London-based Goal Group. There he was responsible for the company’s operations and strategic vision in the Americas and led the company’s worldwide initiatives in securities and antitrust class action litigation services on behalf of its global institutional investor clientele.

Before joining Goal Group, Noah served in similar roles at Stewarts Law as Director of Case Development of Investor Protection Litigation and at Kessler Topaz Meltzer & Check LLP helping global institutional investors exercise their rights to recover for their investment losses pursuant to securities laws in jurisdictions around the world.

Noah is a frequent speaker around the globe on the topic of shareholder legal redress, recovery, rights and responsibilities. He has also been a member of several leading global institutional investor organizations and sits on the International Corporate Governance Network’s (ICGN) Global Stewardship Committee and has previously served on its former Shareholder Responsibilities Committee, the Sovereign Wealth Fund Institute’s Event Advisory Board, and the Council of Institutional Investors’ Markets Advisory Council.

Noah attended Columbia University and the Albert A. List College of the Jewish Theological Seminary of America.

PUBLICATIONS >>

Speaking Engagements >>

Appointments >>

Awards >>

IAN BERG

Partner

Ian Berg serves as a Partner in the firm’s Global Securities Litigation Department, as the head of U.S. Securities Litigation. Ian is an experienced litigator who has represented institutional investors and high-net-worth individuals in U.S. securities class actions and direct actions, leading to the recovery over $4 billion in losses due to alleged fraud and misrepresentations. Ian has strong skills in all aspects of complex litigation, including developing and implementing redress strategies, leading litigation and discovery, and negotiating favorable resolutions. Ian has argued successfully before federal courts throughout the United States, including U.S. Federal District Courts and U.S. Courts of Appeal.

Ian has favorably resolved several U.S. securities class actions while serving as the Court-appointed Lead Counsel, and a number of individual direct actions while serving as the lead litigator on behalf of notable institutional investors and various types of funds. Ian also played an important role on the litigation teams prosecuting some of the largest securities fraud cases brought on behalf of investors in the United States, including the “IPO Securities Litigation” action that encompassed more than 300 companies and 50 investment banks involved in a massive scandal related to IPO practices in the early 2000s and the notorious Tyco securities fraud litigation that recovered over $3 billion for investors.

Ian’s representative cases include:

Lord Abbett Affiliated Fund, Inc., et al. v. American International Group, Inc. et al., 1:15-cv-00774-LTS (S.D.N.Y.)

General Electric Pension Trust, et al. v. American International Group, Inc. et al., 1:15-cv- 00957-LTS (S.D.N.Y.)

City of Orlando Police Pension Fund v. Page, 4:13-cv-02038-PJH (N.D. Cal.)

Pyramid Holdings, Inc. v TerraForm Global, Inc. et al, 1:16-cv-07981-PKC (S.D.N.Y.)

In re Volkswagen “Clean Diesel” Marketing, Sales Practices, and Products Liability Litigation, MDL No. 2672 (CRB); BRS v. Volkswagen AG, et al., 16-cv-3435 (N.D. Cal.) (“Bondholder Securities Action”)

Ian is most proud of his work educating investors about securities litigation. Towards that goal, Ian has been a speaker on various topics and has authored or co-authored the following articles: “Other People’s Money: The Unrealized Conflicts of Securities Lending” (Wall Street Lawyer, July 2010); “Why Institutional Investors Opt-Out of Securities Fraud Class Actions and Pursue Direct Individual Actions” (PLI Securities Litigation and Enforcement Institute, July 23, 2009); “Credit Rating Agencies: Out of Control and in Need of Reform” (Securities Litigation & Regulation Reporter, June 30, 2009); “Ruling Warns Funds to Follow Class Actions” (Pensions & Investments, December 8, 2008); and “The 7th Circuit Sends a Strong Message: Institutions Must Monitor Securities Class Actions Claims” (The NAPPA Report, August 2008).

Ian attended the Northwestern University School of Law and Northwestern University.

MIKE DALY

Partner

Mike Daly is the Managing Partner of Pogust Goodhead’s Philadelphia office.

Mike joined Pogust Millrood (which would later become Pogust Goodhead) in 2014. Prior to joining the firm, Mike was a healthcare litigation lawyer in a large Philadelphia-based defense firm where he represented medical facilities and healthcare professionals in civil liability cases.

At Pogust Goodhead, Mike represents individuals throughout the country in class action and mass tort claims involving consumer fraud, environmental harm, defective medical devices, and harmful pharmaceuticals. Mike spent his first several years at Pogust Goodhead serving as bellwether counsel in the Testosterone Replacement Therapy, Mentor pelvic mesh, GranuFlo dialysate, and Zofran birth injury MDLs. Mike also has managed the firm’s Roundup herbicide litigation and represents hundreds of plaintiffs in their pursuit for justice against the manufacturer of Roundup, Monsanto.

Currently, Mike is serving as lead counsel on behalf of hundreds of individuals in the Injectafer intravenous iron lawsuits pending in Philadelphia state and federal court.

Mike and his team at Pogust Goodhead commenced and have led the Injectafer lawsuits since their inception in 2018.

Mike is also heavily involved in the litigation involving certain hernia mesh products and serves as the Co-Chair of the American Association for Justice (AAJ) Hernia Mesh Litigation Group. He has been appointed to leadership positions in both the Bard Davol Hernia Mesh Litigation that has been coordinated in Rhode Island state court (Plaintiff’s Steering Committee), and continues in his Plaintiffs’ Executive Committee leadership role in the Ethicon Physiomesh, Proceed, and Prolene Hernia System (PHS) multicounty litigation mass torts that involve thousands of plaintiffs injured by Ethicon’s products.

Mike also leads the firm’s efforts in the Abbott formula recall and Necrotizing Enterocolitis (NEC) litigations, as well as the Elmiron vision loss litigation that is pending in the Philadelphia Court of Common Pleas. Mike’s efforts have resulted in millions of dollars in recovery for our firm’s clients.

Since our US firm’s evolution into an international law firm with offices in the US, UK, Netherlands, and Brazil, Mike is busy building products liability litigations on behalf of claimants worldwide, and often relies on the expertise and experience built during his career as a US litigator. In addition to litigating, Mike also serves as a guest speaker on mass torts and products liability matters at seminars both stateside and internationally. Mike has lectured frequently at the American Association for Justice (AAJ) conventions, Harris Martin conventions, and even internationally at a litigation conference held at Oxford University.

On a more informal note, Mike was born, raised, and educated in Pennsylvania and has spent most of his life in the greater Philadelphia region. He is a proud 2007 graduate of Penn State and 2010 graduate of the Villanova School of Law. In his ever-dwindling spare time, Mike remains an active member of Big Brothers Big Sisters Independence Region and a supporter of the Penn State Alumni Association. Of course, Mike’s favorite time is spent away from work with his wife, son, and dog!

JOSHUA NEUMAN

Associate

Joshua Neuman joined Pogust Millrood (now Pogust Goodhead) in 2020.

Prior to joining Pogust Goodhead, Josh was an associate at a premier defense firm in the Philadelphia area, representing medical providers in professional liability actions. Josh also represented putative classes in complex civil litigations against pharmaceutical companies.

At Pogust Goodhead, Josh represents individuals in mass tort, products liability, class action, and personal injury claims. The primary focus of these complex civil matters includes pharmaceutical drugs and devices, consumer fraud, and harmful products. Josh also represents businesses in commercial litigation matters. As an associate, Josh provides insight throughout each phase of the litigation – including the pleadings, discovery, pre-trial, and trial stages.

Josh graduated with Honors from the University of Michigan, and attended Temple University Beasley School of Law. While in Law School, Josh was President of the Jewish Law Students Association and advocated for students’ rights as a conduct board advisor. Following his first year of law school, Josh interned for Judge Angelo J. Foglietta in the Philadelphia Court of Common Pleas, and Judge Mary K. White in the Superior Court of New Jersey. He also clerked for two preeminent Philadelphia law firms, giving him the opportunity to participate in depositions, arbitrations, and settlement negotiations.

Outside of his legal practice, Josh is an active board member of the Greater Philly Hillel Network and the Brandeis Law Society. Josh is also an avid sports fan, and enjoys playing softball, football, volleyball, and golf. Josh resides in Center City Philadelphia with his wife and Boston Terrier, Ernie.